What's happened
UK users of GLP-1 weight-loss meds are rising; the first oral version has approved, and PwC Strategy& warns a shift in spending could accelerate, with more people adopting nutrition, fitness and wellness products.
What's behind the headline?
Critical Analysis
- The data points to a mainstreaming of GLP-1 therapy beyond clinical settings, implying a broader consumer shift in health spending.
- The rise in private access could shift NHS prescribing dynamics and healthcare budgeting, increasing demand for nutritionally aligned products and services.
- Watch for potential market segmentation by age and gender; 60% of users are women, 25–54 is the primary bracket, and 70% access privately.
- The report forecasts a basket reallocation toward nutrition, fitness and confidence products, which may pressure retailers to diversify portfolios.
- This trajectory could reshape grocery and wellness brands, prompting product development aimed at appetite control and satiety.
Forecast
- If trends persist, the UK market may see accelerated growth in GLP-1 supported products and services, with a broader category of weight-management offerings crossing into mainstream consumer goods.
How we got here
PwC Strategy& surveyed 2,300 UK adults and found GLP-1 use could rise from ~3 million to ~7 million by 2027, aided by the Wegovy tablet approval and growing patient interest. Private access remains common, with demographics showing broad appeal across genders, ages, and incomes.
Our analysis
Independent (Anna Wise) reports PwC Strategy& found that UK GLP-1 users could grow from 3 million to 7 million by 2027, aided by the Wegovy pill approval; Sainsbury’s, Marks & Spencer, Waitrose and Greggs have begun nutrient-rich offerings. NOTES: PwC surveyed 2,300 adults; 70% spend less on snacks and 60% spend more on fresh food.
Go deeper
- Will more pharmacies offer GLP-1s or related products privately?
- How might retailers balance safety concerns with consumer demand for appetite-suppressing products?
- What other dietary aids are expected to rise alongside GLP-1 use?